WO2004069140A3 - Antigenes mimant les domaines extracellulaires de proteines membranaires de type iii issues de microorganismes intracellulaires pathogenes, anticorps conformationnels derives et leurs applications - Google Patents

Antigenes mimant les domaines extracellulaires de proteines membranaires de type iii issues de microorganismes intracellulaires pathogenes, anticorps conformationnels derives et leurs applications Download PDF

Info

Publication number
WO2004069140A3
WO2004069140A3 PCT/FR2004/000190 FR2004000190W WO2004069140A3 WO 2004069140 A3 WO2004069140 A3 WO 2004069140A3 FR 2004000190 W FR2004000190 W FR 2004000190W WO 2004069140 A3 WO2004069140 A3 WO 2004069140A3
Authority
WO
WIPO (PCT)
Prior art keywords
pathogenic micro
type iii
imitating
organisms
antigen
Prior art date
Application number
PCT/FR2004/000190
Other languages
English (en)
Other versions
WO2004069140A2 (fr
Inventor
Denis Tranchand-Bunel
Original Assignee
Centre Nat Rech Scient
Univ Rouen
Univ Lille 2
Denis Tranchand-Bunel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Univ Rouen, Univ Lille 2, Denis Tranchand-Bunel filed Critical Centre Nat Rech Scient
Priority to US10/544,081 priority Critical patent/US7803378B2/en
Priority to EP04705828A priority patent/EP1587825A2/fr
Publication of WO2004069140A2 publication Critical patent/WO2004069140A2/fr
Publication of WO2004069140A3 publication Critical patent/WO2004069140A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Antigène dérivé d'un microorganisme intracellulaire pathogène, caractérisé en ce qu'il comprend au moins un fragment peptidique essentiellement constitué par la concaténation des séquences d'au moins deux domaines extracellulaires adjacents dans la structure native d'une protéine membranaire de type III dudit microorganisme intracellulaire pathogène, anticorps conformationnels dérivés, et leurs applications.
PCT/FR2004/000190 2003-01-28 2004-01-28 Antigenes mimant les domaines extracellulaires de proteines membranaires de type iii issues de microorganismes intracellulaires pathogenes, anticorps conformationnels derives et leurs applications WO2004069140A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/544,081 US7803378B2 (en) 2003-01-28 2004-01-28 Antigen imitating extracellular areas of membrane proteins of type III produced from intracellular pathogenic micro-organisms, derived conformational antibodies and the use thereof
EP04705828A EP1587825A2 (fr) 2003-01-28 2004-01-28 Antigenes mimant les domaines extracellulaires de proteines membranaires de type iii issues de microorganismes intracellulaires pathogenes, anticorps conformationnels derives et leurs applications

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0300943A FR2850384A1 (fr) 2003-01-28 2003-01-28 Antigenes mimant les domaines extracellulaires de proteines membranaires de type iii issues de microorganismes intracellulaires pathogenes, anticorps conformationnels derives, et leurs applications
FR03/00943 2003-01-28

Publications (2)

Publication Number Publication Date
WO2004069140A2 WO2004069140A2 (fr) 2004-08-19
WO2004069140A3 true WO2004069140A3 (fr) 2004-09-16

Family

ID=32669284

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2004/000190 WO2004069140A2 (fr) 2003-01-28 2004-01-28 Antigenes mimant les domaines extracellulaires de proteines membranaires de type iii issues de microorganismes intracellulaires pathogenes, anticorps conformationnels derives et leurs applications

Country Status (4)

Country Link
US (1) US7803378B2 (fr)
EP (1) EP1587825A2 (fr)
FR (1) FR2850384A1 (fr)
WO (1) WO2004069140A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3798237A1 (fr) 2010-03-05 2021-03-31 The Johns Hopkins University Compositions et procédés pour des anticorps immunomodulateurs et des protéines de fusion ciblés
WO2011119628A2 (fr) * 2010-03-23 2011-09-29 The Regents Of The University Of California Compositions et méthodes de préparation de vaccins auto-adjuvants contre microbes et tumeurs
CN103068837B (zh) 2010-05-28 2015-06-24 斯匹遐生物技术公司 嵌合momp抗原、方法和使用
AT511582B1 (de) * 2011-10-25 2013-01-15 Moser Adrian Dr Verwendung von keyhole-limpet-hämocyanin oder spaltprodukten davon

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004176A1 (fr) * 1988-10-03 1990-04-19 Scripps Clinic And Research Foundation REGION DE LIAISON DE LA gp350 DE L'EBV AU RECEPTEUR
WO2001037868A1 (fr) * 1999-11-24 2001-05-31 Oklahoma Medical Research Foundation Analyses et therapies utilisees dans le cas d'une infection virale latente
EP1229043A1 (fr) * 2001-01-30 2002-08-07 Cyto-Barr B.V. Peptides derivees des proteines LMP1, LMP2 et BARF1 du virus Epstein Barr
JP2002255997A (ja) * 2001-06-07 2002-09-11 Aichi Prefecture Ｃｄ８＋細胞傷害性ｔリンパ球エピトープペプチド及びその用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO784197A0 (en) * 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
US7091324B2 (en) * 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
CA2468259C (fr) * 2001-12-04 2015-11-24 Dana-Farber Cancer Institute, Inc. Anticorps dirige contre des proteines membranaires latentes (lmp) et utilisations de ceux-ci

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004176A1 (fr) * 1988-10-03 1990-04-19 Scripps Clinic And Research Foundation REGION DE LIAISON DE LA gp350 DE L'EBV AU RECEPTEUR
WO2001037868A1 (fr) * 1999-11-24 2001-05-31 Oklahoma Medical Research Foundation Analyses et therapies utilisees dans le cas d'une infection virale latente
EP1229043A1 (fr) * 2001-01-30 2002-08-07 Cyto-Barr B.V. Peptides derivees des proteines LMP1, LMP2 et BARF1 du virus Epstein Barr
JP2002255997A (ja) * 2001-06-07 2002-09-11 Aichi Prefecture Ｃｄ８＋細胞傷害性ｔリンパ球エピトープペプチド及びその用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE SWISS PROT 21 July 1986 (1986-07-21), "Latent membrane protein 1 (LMP-1) (p63)", XP002289213, Database accession no. P03230 *
TSUKAMOTO K ET AL: "Involvement of Epstein-Barr virus latent membrane protein 1 in disease progression in patients with idiopathic pulmonary fibrosis", November 2000, THORAX, VOL. 55, NR. 11, PAGE(S) 958-961, ISSN: 0040-6376, XP002289267 *
XU J. ET AL.: "Analysis and significance of anti-latent membrane protein-1 antibodies in the sera of patients with EBV-associated diseases.", JOURNAL OF IMMUNOLOGY, vol. 164, no. 5, 2000, pages 2815 - 2822, XP002265599 *

Also Published As

Publication number Publication date
EP1587825A2 (fr) 2005-10-26
US20080075717A1 (en) 2008-03-27
WO2004069140A2 (fr) 2004-08-19
FR2850384A1 (fr) 2004-07-30
US7803378B2 (en) 2010-09-28

Similar Documents

Publication Publication Date Title
BE2016C015I2 (fr)
WO2003011115A3 (fr) Agents de contraste multimères ciblés à base de peptides
PL1699822T3 (pl) Białka fuzyjne IL-7 z częściami przeciwciała, ich otrzymywanie oraz ich zastosowanie
WO2004041865A3 (fr) Anticorps a domaine unique stabilises
WO2001064922A3 (fr) Expression heterologue de proteines issues du gonocoque
WO2006069262A3 (fr) Compositions de proteines virales de la grippe et leurs procedes d'utilisation
DK2316852T3 (da) Stabiliserede enkeltdomæne-antistoffer
EP2289944A3 (fr) Anticorps bispécifiques substituant des protéines fonctionnelles
AU2003209059A1 (en) Human monoclonal antibodies against membrane proteins
WO2004094466A3 (fr) Virus codant une proteine membranaire mutante
WO2005047459A3 (fr) Acides nucleiques du sars, proteines, anticorps et utilisations associees
ATE457352T1 (de) Subtilisin-carlsberg-proteine mit verminderter immunogenität
WO2002077012A3 (fr) Peptides immunoreactifs du papillomavirus humain
WO2004069140A3 (fr) Antigenes mimant les domaines extracellulaires de proteines membranaires de type iii issues de microorganismes intracellulaires pathogenes, anticorps conformationnels derives et leurs applications
WO2005000876A3 (fr) Proteines de la famille des proteines a doigts de zinc (ring finger) et leurs utilisations
TW200634156A (en) Neutralizing epitope-based growth enhancing vaccine
WO2004081033A3 (fr) Synthese de proteines au moyen d'une expression proteique exempte de cellule
WO2005013904A3 (fr) Acides nucleiques, proteines, vaccins contre le sras et leurs utilisations
WO2003031642A3 (fr) Molecules regulatrices de variant love
WO2002074921A3 (fr) Methodes d'isolement de proteines exprimees au moyen de cellules dendritiques
WO2002077648A3 (fr) Antigenes vaccinaux de nesseria pathogenes et commensaux
WO2005047456A3 (fr) Anticorps anti-idiotypiques de l'anticorps monoclonal humain sc-1, leur fabrication et leur utilisation
BR0303226A (pt) Proteìnas de aderência e penetração de haemophilus
AU2002325299A1 (en) Novel t-cell proteins, peptides and antibodies derived therefrom and uses thereof
AU2013245463B2 (en) Immunoglobulin Chimeric Monomer-Dimer Hybrids

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004705828

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004705828

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10544081

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10544081

Country of ref document: US